KOL Perspectives: Mid-to-Late Stage Pipeline Therapies in Lupus
Orbisresearch.com published “Mid-to-Late Stage Pipeline Therapies in Lupus Market” from its database. The report focuses on major leading industry players with information such as company profiles, product picture and specification.
(EMAILWIRE.COM, October 24, 2018 ) This KOL Insight briefing focuses on opinions of mid- to late-stage pipeline therapies in lupus.
The briefing includes analysis of KOL opinion on the following topic areas -
- Development of Lupuzor for SLE
- Lupuzor’s Phase III trial design
- Lupuzor’s Phase IIb efficacy data in SLE
- Anticipated future use of Lupuzor in SLE
- Development of baricitinib in SLE
- Endpoints used in baricitinib’s Phase II trial
- Expectations for baricitinib’s Phase II trial results
- Views on the increased risk of thromboembolic events seen with baricitinib in RA
- Views on the risk of thromboembolic events in the lupus patient population
- Concerns regarding herpes zoster in lupus patients
- Impact of high infection rate with JAK inhibitor use in RA, on anticipated baricitinib use in SLE
- Development of IFN? kinoid in SLE
- IFN? kinoid vs. anifrolumab in SLE
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2350554
Key Highlights:
- Most KOLs flagged the need for more data to understand Lupuzor’s mechanism of action and elucidate its efficacy in lupus patients
- KOLs were divided over Lupuzor’s efficacy in lupus based on its Phase IIb data, with some highlighting that it may be comparable to belimumab
- Most KOLs had a positive opinion regarding baricitinib’s development in lupus, based on its data in other indications.
Key Players:
• ImmuPharma
• AstraZeneca
• Lilly
Scope:
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our lupus key opinion leaders (KOLs)
- In total, we conducted interviews with 14 KOLs: Seven Europe-based & seven US-based
- Interviews performed in December 2017
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.
Reasons to buy:
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Mid-to-Late Stage Pipeline Therapies in Lupus"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2350554
Key Points from TOC:
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
The briefing includes analysis of KOL opinion on the following topic areas -
- Development of Lupuzor for SLE
- Lupuzor’s Phase III trial design
- Lupuzor’s Phase IIb efficacy data in SLE
- Anticipated future use of Lupuzor in SLE
- Development of baricitinib in SLE
- Endpoints used in baricitinib’s Phase II trial
- Expectations for baricitinib’s Phase II trial results
- Views on the increased risk of thromboembolic events seen with baricitinib in RA
- Views on the risk of thromboembolic events in the lupus patient population
- Concerns regarding herpes zoster in lupus patients
- Impact of high infection rate with JAK inhibitor use in RA, on anticipated baricitinib use in SLE
- Development of IFN? kinoid in SLE
- IFN? kinoid vs. anifrolumab in SLE
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2350554
Key Highlights:
- Most KOLs flagged the need for more data to understand Lupuzor’s mechanism of action and elucidate its efficacy in lupus patients
- KOLs were divided over Lupuzor’s efficacy in lupus based on its Phase IIb data, with some highlighting that it may be comparable to belimumab
- Most KOLs had a positive opinion regarding baricitinib’s development in lupus, based on its data in other indications.
Key Players:
• ImmuPharma
• AstraZeneca
• Lilly
Scope:
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our lupus key opinion leaders (KOLs)
- In total, we conducted interviews with 14 KOLs: Seven Europe-based & seven US-based
- Interviews performed in December 2017
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.
Reasons to buy:
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Mid-to-Late Stage Pipeline Therapies in Lupus"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2350554
Key Points from TOC:
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results